Article
Pre-infusion plasma proteomics identifies an endothelial–immune priming signature predictive of severe cytokine release syndrome and neurotoxicity following CAR T-cell therapy in relapsed/refractory lymphoma
2026-03-31
Abstract excerpt
<h4>Background</h4> Severe cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) remain frequent, life-threatening complications of CD19 chimeric antigen receptor (CAR) T-cell therapy and constrain its safety, scalability, and outpatient adoption. Existing predictive models lack sufficient external validation for routine clinical use, and pre-infusion biomarkers that c...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 4c8004e9-7fff-5ce6-b96d-f3d6199d2437
- DOI
- 10.64898/2026.03.29.26349664
